Mechanism of Action definition

Mechanism of Action means, with respect to a target, modulation of such target by a compound via a given mechanism of action (whether inhibition or activation).
Mechanism of Action means Orexin-1 receptor antagonism,
Mechanism of Action or “MOA” means each of the DCM1 MOA, the HCM1 MOA and the HCM2 MOA.

Examples of Mechanism of Action in a sentence

  • Shi, Antibacterial Activity and Mechanism of Action of Zinc Oxide Nanoparticles against Campylobacter jejuni, Appl.

  • Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.

  • Juncai, Antibacterial Activity and Mechanism of Action of Bovine Lactoferricin Derivatives with Symmetrical Amino Acid Sequences, Int.

  • Jiang, Antibacterial Activity and Mechanism of Action of Bovine Lactoferricin Derivatives with Symmetrical Amino Acid Sequences, Int.

  • Epigenetic gene regulation governed by BET proteins is at the core of many CVD pathological processes – dysregulation of multiple pathways contributes to increased risk and worse cardiovascular outcomes Epigenetic Mechanism of Action: Single Therapeutic Target with Multiple Biological Effects BET inhibition results in the simultaneous modulation of multiple biological pathways via a single molecular target.


More Definitions of Mechanism of Action

Mechanism of Action means the binding to the nuclear export protein, Exportin 1, or XPO1, causing inhibition of the activity of XPO1 or otherwise reducing the nuclear export of XPO1’s cargo proteins.
Mechanism of Action or “MoA” means the results on the [********] criteria set forth on Schedule 1.82 (based on the corresponding measurement set forth on Schedule 1.82) at the applicable Protein Target Profile, taking each such criterion into account. A compound has “substantially the same” Mechanism of Action or MoA as another compound if (i) the two compounds have the same Protein Target Profile and the results of the first compound and the second compound on each of such measurements at [********] the NNR Subtypes included in the applicable Protein Target Profile are [********] for such measurement shown on Schedule 1.82 (provided that, where there are alternative measurements (or assays used to make such measurement) that may be applicable for a particular criterion (i.e., [********]) determination of whether any compound has substantially the same Mechanism of Action as another compound shall be made using the same measurement(s) (or assay(s)) as was used by Targacept to make such measurement with respect to such first compound) and (ii) neither compound has activity in any material respect [********] at which the other compound does not have activity in any material respect.
Mechanism of Action means that the relevant Third Party FOB binds to the same antigen as the Product.
Mechanism of Action means, with respect to a Checkpoint Blockade Agent, [***].
Mechanism of Action. The epipodophyllotoxins exert phase specific spindle poison activity with metaphase arrest, but in contrast to the vinca-alkaloids, have an additional activity of inhibiting cells from entering mitosis. Suppression of tritiated thymidine, uridine, and leucine incorporation in human cells in tissue culture suggests effects against DNA, RNA, and protein synthesis.
Mechanism of Action means the specific biological and/or chemical interaction(s) through which a drug substance produces its pharmacological effect(s).
Mechanism of Action means [***] "Net Sales" means, with respect to a Licensed Product, for any reference period, the gross amount invoiced by[***] : (a) [***]; (b) [***]; (c) [***]; (d) [***]; (e) [***]; (f) [***]; and (a) to (f) shall be referred to as the "Deductions"); sales of Licensed Product between or among TOI, its Affiliates and/or Sublicensees shall be excluded from the computation of Net Sales, but the subsequent final sales of Licensed Product to Third Parties by such Affiliates or Sublicensees shall be included in the computation of Net Sales. For purposes of calculating Net Sales, a sale to an Affiliate or Sublicensee for end use by the Affiliate or Sublicensee (as the applicable) will be treated as a sale at [***]. "Patent" means (a) unexpired and currently in force patents (or other equivalent legal instrument), including utility and design patents, supplementary protection certificates and including any extension, limitation, substitution, registration, confirmation, reissue, re-examination or renewal thereof, (b) applications for patents, a reissue application, a continuation application, a continuation-in-part application, a divisional application or any equivalent of the foregoing applications, that are pending before a government patent authority and (c) all foreign or international equivalents of any of the foregoing in any country; "Person" means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof; "Phase I Clinical Trials" means any clinical study of a Licensed Product in human the purpose of which is preliminary determination of safety of such Licensed Product in healthy individuals or patients that would satisfy the requirements of 21 C.F.R. §312.21(a) in the U.S. or equivalent law or regulations in other countries; such first in man study can also look at preliminary signs of efficacy in patients; Phase I Clinical Trials includes notably Phase I, Phase Ia and Phase Ib Clinical Trials; "Phase II Clinical Trials" means any clinical study of a Licensed Product in human patients of defined disease parameters the purpose of which is further determination of the clinical safety, dose response, duration of effect, dose range and efficacy of such Licensed Product that would